BRISTOL MYERS SQUIBB CO

BMY Healthcare & Pharma 4/10 Medium Risk
4/10

BRISTOL MYERS SQUIBB CO has $49.4B in total long-term debt with $14.3B in scheduled maturities. Approximately $2.0B (14% of maturities) is due within the next twelve months. Overall, BMY carries moderate refinancing risk (score 4/10).

Maturity Schedule

Year 1 $2.0B Year 2 $2.0B Year 3 $544M Year 4 $2.2B Year 5 $2.1B Beyond 5 $5.5B
Period Amount Due % of Total
Year 1 (0-12 months) $2.0B 13.9%
Year 2 (12-24 months) $2.0B 13.9%
Year 3 (24-36 months) $544M 3.8%
Year 4 (36-48 months) $2.2B 15.3%
Year 5 (48-60 months) $2.1B 14.6%
Beyond 5 Years $5.5B 38.3%
Total Scheduled Maturities $14.3B 100.0%

Key Metrics

Total Long-Term Debt
$49.4B
Near-Term (12mo)
$2.0B
Interest Coverage
N/A
Debt/Equity
3.03
Cash Coverage
5.17x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 13.9% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 3.03 25%
Cash Coverage of Near-Term Debt 5.17x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-11. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.